Intellia Therapeutics, Inc. (NASDAQ:NTLA) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc.
Research analysts at Oppenheimer Holdings, Inc. assumed coverage on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a note issued to investors on Tuesday. The firm set a “market perform” rating on the stock.
A number of other research firms also recently issued reports on NTLA. Cann reiterated a “market perform” rating on shares of Intellia Therapeutics in a report on Monday. TheStreet upgraded shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Monday, May 15th. Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a report on Thursday, June 22nd. Finally, Credit Suisse Group set a $24.00 price objective on shares of Intellia Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $25.71.
Intellia Therapeutics (NTLA) traded down 8.1823% on Tuesday, reaching $15.2601. 275,612 shares of the company’s stock traded hands. Intellia Therapeutics has a 52-week low of $10.83 and a 52-week high of $24.90. The stock’s 50 day moving average is $13.75 and its 200 day moving average is $13.83. The firm’s market cap is $549.79 million.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. Intellia Therapeutics had a negative net margin of 179.64% and a negative return on equity of 17.65%. The business had revenue of $6.22 million during the quarter, compared to analyst estimates of $5.30 million. On average, equities research analysts predict that Intellia Therapeutics will post ($1.59) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/18/intellia-therapeutics-inc-nasdaqntla-coverage-initiated-by-analysts-at-oppenheimer-holdings-inc.html.
In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of Intellia Therapeutics stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 12.80% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of the company. GLG Partners LP purchased a new position in shares of Intellia Therapeutics during the second quarter worth $100,000. IHT Wealth Management LLC purchased a new position in shares of Intellia Therapeutics during the first quarter worth $117,000. Bank of Montreal Can increased its position in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares during the last quarter. Nisa Investment Advisors LLC purchased a new position in shares of Intellia Therapeutics during the second quarter worth $134,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Intellia Therapeutics during the first quarter worth $137,000. Institutional investors and hedge funds own 47.07% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.